about
Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operationGenomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreakLassa fever in post-conflict sierra leoneEbola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra LeoneRoots, Not Parachutes: Research Collaborations Combat OutbreaksIdentification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparumMost neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunitsVirus genomes reveal factors that spread and sustained the Ebola epidemicWorld Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria.Effects of mefloquine and artesunate mefloquine on the emergence, clearance and sex ratio of Plasmodium falciparum gametocytes in malarious children.Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapyFactors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children.Risk factors for Plasmodium falciparum hyperparasitaemia in malarious childrenResearch capacity. Enabling the genomic revolution in Africa.Rapid detection of lactate dehydrogenase and genotyping of Plasmodium falciparum in saliva of children with acute uncomplicated malariaNomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014.Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples.Empowering African genomics for infectious disease control.Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments.Clinical illness and outcomes in patients with Ebola in Sierra Leone.Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance.Discovery of novel rhabdoviruses in the blood of healthy individuals from West Africa.Genome-wide scans provide evidence for positive selection of genes implicated in Lassa feverActivities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites in falciparum malaria in childrenClinical Sequencing Uncovers Origins and Evolution of Lassa VirusEarly rising asexual parasitaemia in Nigerian children following a first dose of artemisinin-based combination treatments of falciparum malaria.In vitro-reduced susceptibility to artemether in P. falciparum and its association with polymorphisms on transporter genesA qualitative study of the feasibility and community perception on the effectiveness of artemether-lumefantrine use in the context of home management of malaria in south-west Nigeria.Plasmodium falciparum gametocyte sex ratios in children with acute, symptomatic, uncomplicated infections treated with amodiaquine.Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan AfricaEbola Virus Epidemiology and Evolution in Nigeria.A simple cost-effective high performance liquid chromatographic assay of sulphadoxine in whole blood spotted on filter paper for field studies.Population structure of Plasmodium falciparum gametocyte sex ratios in malarious children in an endemic area.Therapeutic efficacy and effects of artemisinin-based combination treatments on uncomplicated Plasmodium falciparum malaria -associated anaemia in Nigerian children during seven years of adoption as first-line treatmentsAn Outbreak of Ebola Virus Disease in the Lassa Fever Zone.Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa.Prevalence of Lassa Virus Disease (LVD) in Nigerian children with fever or fever and convulsions in an endemic area.Cultural categorization of febrile illnesses in correlation with herbal remedies used for treatment in Southwestern Nigeria.In Vitro and In Vivo Antimalarial Activity of Ficus thonningii Blume (Moraceae) and Lophira alata Banks (Ochnaceae), Identified from the Ethnomedicine of the Nigerian Middle Belt.Epidemiology. Emerging disease or diagnosis?
P50
Q21092277-11613251-07B4-44AC-9902-CA723F08F1DDQ23000449-E70B6ADE-ECF9-443C-A9ED-2B5038DC92F5Q24290732-A838388F-C0E9-474C-98FE-7F1C608315DDQ24696014-A4D26B83-1C18-451F-9E57-B627F3383FC9Q25197488-CE6AF9A1-7519-4D93-ADCF-8C50ED884701Q28477846-E194C12F-F045-4103-8363-FB1D775E7ACDQ28602816-8B4F3B44-71E2-408F-A527-75A960017AC5Q29394299-E9D5E9DD-7EE4-4FB3-8B9E-2C003810F3EFQ30483555-D7ADC39E-2FB9-4314-A850-728E08A6220AQ33587420-4FFDC451-D48F-4966-9A16-9295C0CF4BB7Q33596081-49E88E25-16DB-4D2D-AED4-FEEC7592D2E7Q33711891-BA475EE5-C20B-4101-B349-B2F70F6E3B80Q34044042-23E4A41F-7C6E-4292-B172-F568B09E4A81Q34068017-1A3CC36A-27D4-4268-B01E-1604C4D93F40Q34087300-9146C60D-2CBD-4915-B721-5E0F92630D19Q34580917-0AF72C77-1F35-470F-AE06-26F0F9FA5B73Q34676766-1A48095F-40C9-4549-A960-214E6319A2F2Q34803134-659563CC-A39A-44A0-BDAB-5380C73C39D5Q35031900-1F832F50-4852-419A-A4D3-E3F3F9D67C3AQ35053891-0607A76D-CD58-4F4D-A040-7FAFE3A99722Q35154559-2C07A326-1EDB-4C17-9B66-1050BEB9CEC1Q35187816-B196AD24-3EB7-48DC-91F0-B83C34C357DEQ35701103-8FCADD37-A8BB-4CD9-AB93-E0F36935B9D0Q35759098-A5AA29E3-FD2C-465C-88DA-55422E795D31Q35957928-3E2BE1B0-3A18-4C6F-A7A3-354496DD5E61Q36265393-CD4D6C3A-3A60-4AB3-9066-1FBFBC98D7D7Q36376217-9A280E84-2B36-4CCF-BE73-63685D934944Q36724458-72F17E84-651B-4D88-997F-8BAAAAD5EB8AQ36889810-CFEFFA10-96C3-42CB-AC8D-9665D89AB9F6Q36936673-535EF3AE-2716-4483-9B6C-A4A89C15281FQ37310759-464180B5-FFA1-4894-B209-B62D41DAA801Q37413041-FD692540-9E94-48D8-9323-2819F8E2223BQ37434808-312E51D8-D661-4ACD-A6FA-52F37339B3F0Q37628066-4DB71F1F-B12E-4990-93AE-8E4D5305C7BDQ38378926-13677EF7-3BC5-48E2-906A-9915FCDF47BCQ38470818-855F1B28-357A-4E56-B3A5-6687050C4757Q38696655-003251F3-CF02-49C4-B7C4-D6C6B2860668Q38864638-8E59B3AE-A788-49D0-A9E6-D71B1D0816DDQ38982095-FC008E12-0530-401A-951D-8D3542838488Q39024491-F451AFA0-8AD6-4BD7-81F2-22C9F4E2230F
P50
description
biologist
@en
name
Christian T. Happi
@en
Christian T. Happi
@nl
type
label
Christian T. Happi
@en
Christian T. Happi
@nl
altLabel
C Happi
@en
C T Happi
@en
C. Happi
@en
C. T. Happi
@en
Christian Happi
@en
Christian T Happi
@en
Happi C
@en
Happi C. T.
@en
Happi C.
@en
Happi CT
@en
prefLabel
Christian T. Happi
@en
Christian T. Happi
@nl
P31
P496
0000-0002-3056-6705